<?xml version='1.0' encoding='utf-8'?>
<document id="20000889"><sentence text="Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole."><entity charOffset="110-122" id="DDI-PubMed.20000889.s1.e0" text="itraconazole" /></sentence><sentence text="For compounds with a long elimination half-life, the evaluation of a drug-drug interaction (DDI) study can be challenging" /><sentence text=" The standard analytical approach of a non-compartmental analysis (NCA) might not be able to detect the full interaction potential and may lead to a significant underestimation of the interaction" /><sentence text=" The most appropriate method for data analysis might be a semi-mechanistic population pharmacokinetic modelling approach" /><sentence text="" /><sentence text="To accomplish a semi-mechanistic DDI model for a long-elimination-half-life drug substrate, tesofensine, and the cytochrome P450 (CYP) 3A4 inhibitor itraconazole, and to compare the results of the semi-mechanistic model with the results obtained from the standard NCA approach"><entity charOffset="92-103" id="DDI-PubMed.20000889.s6.e0" text="tesofensine" /><entity charOffset="149-161" id="DDI-PubMed.20000889.s6.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.20000889.s6.e0" e2="DDI-PubMed.20000889.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s6.e0" e2="DDI-PubMed.20000889.s6.e1" /></sentence><sentence text=" Additionally, the impact of different schedules of itraconazole on tesofensine pharmacokinetics and the general performance of the standard NCA approach were evaluated"><entity charOffset="52-64" id="DDI-PubMed.20000889.s7.e0" text="itraconazole" /><entity charOffset="68-79" id="DDI-PubMed.20000889.s7.e1" text="tesofensine" /><pair ddi="false" e1="DDI-PubMed.20000889.s7.e0" e2="DDI-PubMed.20000889.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s7.e0" e2="DDI-PubMed.20000889.s7.e1" /></sentence><sentence text="" /><sentence text="Overall, 28 subjects received a single oral dose of tesofensine 2 mg; 14 of these subjects were coadministered an oral itraconazole 400 mg loading dose and a 200 mg maintenance dose for 6 days before and 5 days after administration of tesofensine"><entity charOffset="52-63" id="DDI-PubMed.20000889.s9.e0" text="tesofensine" /><entity charOffset="119-131" id="DDI-PubMed.20000889.s9.e1" text="itraconazole" /><entity charOffset="235-246" id="DDI-PubMed.20000889.s9.e2" text="tesofensine" /><pair ddi="false" e1="DDI-PubMed.20000889.s9.e0" e2="DDI-PubMed.20000889.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s9.e0" e2="DDI-PubMed.20000889.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20000889.s9.e0" e2="DDI-PubMed.20000889.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20000889.s9.e1" e2="DDI-PubMed.20000889.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20000889.s9.e1" e2="DDI-PubMed.20000889.s9.e2" /></sentence><sentence text=" The dataset contained 465 plasma concentrations of tesofensine (full profiles) and 80 plasma concentrations of itraconazole (trough values)"><entity charOffset="52-63" id="DDI-PubMed.20000889.s10.e0" text="tesofensine" /><entity charOffset="112-124" id="DDI-PubMed.20000889.s10.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.20000889.s10.e0" e2="DDI-PubMed.20000889.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s10.e0" e2="DDI-PubMed.20000889.s10.e1" /></sentence><sentence text=" First, pharmacokinetic models of itraconazole and tesofensine were developed in parallel"><entity charOffset="34-46" id="DDI-PubMed.20000889.s11.e0" text="itraconazole" /><entity charOffset="51-62" id="DDI-PubMed.20000889.s11.e1" text="tesofensine" /><pair ddi="false" e1="DDI-PubMed.20000889.s11.e0" e2="DDI-PubMed.20000889.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s11.e0" e2="DDI-PubMed.20000889.s11.e1" /></sentence><sentence text=" Subsequently, a combined model was developed, taking into account CYP3A4 inhibition" /><sentence text=" The analyses were performed using NONMEM software" /><sentence text="" /><sentence text="The plasma concentration-time profiles of itraconazole and tesofensine were best described by a one-compartment model for each drug, with first-order elimination rate constants that were both inhibited by itraconazole concentrations"><entity charOffset="42-54" id="DDI-PubMed.20000889.s15.e0" text="itraconazole" /><entity charOffset="59-70" id="DDI-PubMed.20000889.s15.e1" text="tesofensine" /><entity charOffset="205-217" id="DDI-PubMed.20000889.s15.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.20000889.s15.e0" e2="DDI-PubMed.20000889.s15.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s15.e0" e2="DDI-PubMed.20000889.s15.e1" /><pair ddi="false" e1="DDI-PubMed.20000889.s15.e0" e2="DDI-PubMed.20000889.s15.e2" /><pair ddi="false" e1="DDI-PubMed.20000889.s15.e1" e2="DDI-PubMed.20000889.s15.e1" /><pair ddi="false" e1="DDI-PubMed.20000889.s15.e1" e2="DDI-PubMed.20000889.s15.e2" /></sentence><sentence text=" Inhibition resulted in reduced clearances and prolonged elimination half-lives for tesofensine and itraconazole: using NCA, the actual study revealed an approximately 9% increase in exposure for the timeframe of the coadministration with itraconazole (the area under the plasma concentration-time curve (AUC) from 0 to 144 hours [AUC(144h)]), and the impact on exposure estimated to infinity (AUC(infinity)) was approximately 26%"><entity charOffset="84-95" id="DDI-PubMed.20000889.s16.e0" text="tesofensine" /><entity charOffset="100-112" id="DDI-PubMed.20000889.s16.e1" text="itraconazole" /><entity charOffset="239-251" id="DDI-PubMed.20000889.s16.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.20000889.s16.e0" e2="DDI-PubMed.20000889.s16.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s16.e0" e2="DDI-PubMed.20000889.s16.e1" /><pair ddi="false" e1="DDI-PubMed.20000889.s16.e0" e2="DDI-PubMed.20000889.s16.e2" /><pair ddi="false" e1="DDI-PubMed.20000889.s16.e1" e2="DDI-PubMed.20000889.s16.e1" /><pair ddi="false" e1="DDI-PubMed.20000889.s16.e1" e2="DDI-PubMed.20000889.s16.e2" /></sentence><sentence text=" These results are in contrast to the model-predicted results, where the inhibitory effect of itraconazole caused a 38% reduction in the clearance of tesofensine, leading to a 63% increased exposure"><entity charOffset="94-106" id="DDI-PubMed.20000889.s17.e0" text="itraconazole" /><entity charOffset="150-161" id="DDI-PubMed.20000889.s17.e1" text="tesofensine" /><pair ddi="false" e1="DDI-PubMed.20000889.s17.e0" e2="DDI-PubMed.20000889.s17.e0" /><pair ddi="false" e1="DDI-PubMed.20000889.s17.e0" e2="DDI-PubMed.20000889.s17.e1" /></sentence><sentence text="" /><sentence text="This analysis presents a semi-mechanistic population pharmacokinetic approach that may be useful for the evaluation of DDI studies" /><sentence text=" The model can be an aid in evaluating DDI studies for compounds with a long elimination half-life, especially when the inhibitor cannot be administered over a sufficient period" /><sentence text=" Additionally, the population model-based approach may allow simplification of the design and the analysis and interpretation of safety and efficacy findings in DDI studies" /><sentence text="" /></document>